UNSPSC 51343115: Zalcitabine

This classification denotes a pyrimidine antagonist with the molecular formula C9H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L3XT8CB3I, chemically known as dideoxycytidine but generally known as zalcitabine, which bears US NIH Compound Identifier 24066. European Medicines Agency schedules Zalcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00130MIG.

UNSPSC 51343115 Zalcitabine, a Commodity code, shows substantial mismatch between its nominal scope—a specific antiretroviral pharmaceutical—and actual state and local procurement activity under the code. Recent opportunities tagged to this code do not solicit zalcitabine itself but instead reflect broader pharmaceutical and medical supply procurement across health departments, fire rescue divisions, and cooperative purchasing alliances. State and local governments are buying naloxone and drug deactivation systems, emergency medical consumables (cardiac electrodes, endotracheal tubes, airway devices, bandaging materials), generic multi-source pharmaceuticals distributed through authorized wholesalers, and exploring direct-to-manufacturer prescription programs through pharmacy benefit initiatives. Issuing bodies include county health departments (Seminole County, Florida), city purchasing offices supporting emergency response (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for naloxone and safe drug deactivation systems (IFB 60459723LAS, due July 26, 2023, with quarterly deliveries to the Community Health Building); the City of Tampa's IFB for medical and first aid supplies supporting the Fire Department Rescue Division (IFB 26-P-00145, due March 13, 2026, estimated at $700,000, with a 5 percent SLBE bid discount capped at $10,000); the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (RFI HHS0017013, response deadline April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026, effective July 1, 2026 through June 30, 2028). The code appears to capture pharmaceutical procurement broadly rather than the specific active ingredient its name denotes, making activity tracking and scope alignment challenging for vendors targeting this classification.